Skip Menu

Premature Ejaculation Profile (PEP)

A four-question instrument that measures the primary impacts of premature ejaculation using individual items.

Patrick DL, Giuliano F, Gagnon DD, Rothman M - International Study Group for the PEP
Research & Intervention Studies
Sexual Dysfunction
Male, 18 and older
Type of Instrument
Quality of Life
Mode of Administration
Time recall
Last month
Number of Items
4 items

List of Existing Translations:

  • Afrikaans (South Africa), Bulgarian (Bulgarian), Chinese- Simplified (China, Malaysia, Singapore), Chinese- Traditional (Hong Kong, Taiwan), Czech (Czech Republic), Dutch (Belgium, Netherlands), English (Australia, Malaysia, Philippines, Singapore, US), Finnish (Finland), French (Belgium, Canada, France), German (Germany), Hebrew (Israel), Hungarian (Hungary), Italian (Italy), Korean (South Korea), Malay (Malaysia, Singapore), Norwegian (Norway), Polish (Poland), Portuguese (Brazil, Portugal), Spanish (Argentina, Mexico, Spain, US) Spanish- Universal, Swedish (Sweden), Tagalog (Philippines), and Thai (Thailand)

Validation Reference(s):

1. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. (2009). The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU International, 103(3) 358-64.

2. Mathers MJ, Sommer F, Degener S, Brandt AS, Roth S. (2013). [Premature ejaculation in urological routine practice]. Aktuelle Urologie, 44(1), 33-9.

3. Sato Y, Tanda H, Nakajima H, Nitta T, Akagashi K, Hanzawa T, Tobe M, Haga K, Uchida K, Honma I. (2012). Silodosin and its potential for treating premature ejaculation: a preliminary report. International Journal of Urology, 19(3), 268-72.

4. David Prologo J, Snyder LL, Cherullo E, Passalacqua M, Pirasteh A, Corn D. (2013). Percutaneous CT-guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. J Vasc Interv Radiol, 24(2), 214-9.

5. Akin Y, Gulmez H, Ates M, Bozkurt A, Nuhoglu B. (2013). Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iran Red Crescent Med J, 15(10):e13805.

6. Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, Cho JS, Lee SK, Yang DY. (2013). Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med, 10(11), 2832-41.

7. McMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, Sharma O, Rivas DA, Aquilina JW. (2013). Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. J Sex Med, 10(9), 2312-25.

8. McMahon CG. (2012). Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol, 4(5), 233-51.

9. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, Ekmekcioglu O, Kendirci M, Semerci B, Kadioglu A. (2011). The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. J Sex Med, 10(11), 2832-41.

10. Bar-Or D, Salottolo KM, Orlando A, Winkler JV; Tramadol ODT Study Group. (2012). A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol, 61(4), 736-43.

11. Hoy SM, Scott LJ. (2010). Dapoxetine: in premature ejaculation. Drugs. 70(11), 1433-43.

12. McMahon CG. (2011). Efficacy of dapoxetine in the treatment of premature ejaculation. Clin Med Insights Reprod Health, 5, 25-39.

13. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Porst H. (2011). Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 8(2), 524-39.

14. McMahon CG. (2010). Dapoxetine for premature ejaculation. Expert Opin Pharmacother, 11(10), 1741-52.

15. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J, Dapoxetine 3003 Study Investigators. (2010). Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med, (1 Pt 1), 256-68.

16. Jern P, Piha J, Santtila P. (2013). Validation of three early ejaculation diagnostic tools: a composite measure is accurate and more adequate for diagnosis by updated diagnostic criteria. PLoS One, 8(10):e77676.

17. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. (2009). Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int, 103(5), 651-8.

18. Dinsmore WW, Wyllie MG. (2009). PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int, 103(7), 940-9.

19. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. (2009). Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol, 55(4), 957-67.

20. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E; 3004 Study Group. (2008). Premature ejaculation: results from a five-country European observational study. Eur Urol, 53(5), 1048-57.

21. Rowland DL, Patrick DL, Rothman M, Gagnon DD. (2007). The psychological burden of premature ejaculation. J Urol, 177(3), 1065-70.

Additional Information: